----
Current ValuationThe current P/E ratio is 12.10, below the reasonable range, cheaper than 83.59% of the time in the past 5 years, and the industry ranks 5/74, the industry Median --.
12.1xP/E
$22.68Stock price
$1.88Earnings per share
12.1xP/E
Stock price$22.68Earnings per share$1.88
Historical Valuation
P/E ratioTypical rangeMedian
- P/E ratio
- 18.82x
- Typical range
- 12.64x–22.21x
Peer P/E ratio Comparison
It displays how the company's P/E ratio compares to top companies within its industry.
07142128
The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.
Industry P/E ratio Comparison
This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x40x80x120x160x200x
| Name/Symbol | |||
|---|---|---|---|
CIUSCigna | 12.64x | 11.90% | $81.11B |
FMSUSFresenius Medical Care | 12.10x | 27.16% | $13.15B |
DVAUSDaVita | 13.82x | 48.02% | $11.72B |
AVAHUSAveanna Healthcare | 10.63x | 31.53% | $2.92B |
MDUSPediatrix Medical | 13.61x | 1.36% | $2.38B |
AMNUSAMN Healthcare Services | 17.72x | 174.65% | $1.86B |
SBCUSSBC Medical | 11.08x | 6.50% | $543.03M |
SRTAUSStrata Critical Medical | 10.25x | 61.46% | $412.26M |
NIVFUSNewGenIvf | 1.60x | 97.79% | $1.79M |
Risk Warning
Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.
